Concordia Healthcare Corp. T.CXR.R

RE:RE:Liar! Liar! Bras on Fire

[capmorgan]

In defence of Lattice, she did correct herself. Her first post on this article was incorrect and she posted a Sept article , which read that it was. Target of $6.50. But Lattice's comments said a $3.50 target which didn't match the article. But Latice's next posting corrected her mistake , and posted the new article. Now, one could argue if this was posted to mislead readers , none the less this was corrected By Lattice.

LaticelnExile wrote:daveinmiss.. I would suggest that you learn how to use the internet and stop accusing me of lying or you may want to get some help before you lose any more money. Laurentian cut their target yesterday to $3.50 after the debt offering by Concordia. Sheesh..... a nine year old has more competent internet search skills than you have.

I have cut and pasted the article and hopefully it will not be obscured by Stockhouse advertising. Furthermore I have also provided a direct link as it appears that you either 1) have a literacy problem or 2) you can not navigate the internet; or 3) just routinely call shorties liars because you under different aliases because you can't think of anything else to say.

Have a fabulous baggie day and equally great weekend!

[url=https://https://www.cantechletter.com/2016/10/laurentian-cuts-price-target-concordia-international/][/url

Laurentian cuts price target on Concordia International

BY NICK WADDELL0 COMMENTS

Concordia Healthcare CEO Mark Thompson.

A proposed debt offering has taken Laurentian Bank Securities analyst Joseph Walewicz by surprise and left him feeling bearish about Concordia International (TSX:CXR).

Yesterday, Concordia announced it intends to commence a senior note offering to raise up to $350-million. Management said the proceeds would be used to “strengthen the company’s liquidity position and augment its product development pipeline beyond the anticipated, and previously disclosed, 60 product launches, expected by the fourth quarter of 2018.”

Walewicz says this debt offering suggests forthcoming results that will be weaker than he had forecast

“We had forecasted that CXRX had sufficient cash flows to meet its obligations, including the upcoming earn outs for the AMCo transaction. With this offering the company is signalling that it needs additional capital to meet the earn outs (£72M in Q4/16, and another ~£74M in Q1/17). We should get greater clarity about the pro forma outlook when CXR reports in a few weeks,” says the analyst, adding: “Unfortunately, we see no near term catalysts for the stock.”

In a research update to clients today, Walewicz lowered his rating on Concordia International from “Hold” to “Reduce” and cut his one-year price target on the stock from (U.S) $6.50 to $3.50.

Walewicz thinks Concordia will lose $592.6-million on revenue of $876.2-million in fiscal 2016. He expects the company’s bottom line will improve to earnings of $267.2-million on a topline of $858.1-million the following year.

daveinmiss wrote: Latice...you do have cheek. Calling someone a liar based on your history of blatant untruths.
For example, you posted "In a research update to clients today, Walewicz lowered his rating on Concordia International from “Hold” to “Reduce” and cut his one-year price target on the stock from (U.S) $6.50 to $3.50."
Whereas, the article says, "In a research update to clients today, Walewicz maintained his “Hold” rating and cut his price target on Concordia Healthcare from (U.S.) $12.00 to $6.50."

That you would knowingly try to deceive this Board diminishes your credibility.

I still work, so I only visit the Board once every couple days and I must say, you seem to your credit to have done your research and when you are not making obtuse comments, have some valid input.
That said, it appears to me you are on here most of the time, and maybe you make your living doing this which is fair enough but otherwise, my free advice is GET A LIFE.